CURE targets three times the daily move of the Health Care Select Sector Index — large-cap pharmaceutical companies, insurers, device makers and health services. It is a far steadier instrument than the biotech funds, because the underlying sector is dominated by profitable, established businesses rather than clinical-stage speculation.
Direxion Daily Healthcare Bull 3X ETF (CURE) is currently trading at $144.96. Over the past 52 weeks, CURE has traded between a low of $74.34 and a high of $150.00. Recent daily volume is around 114.8K. These figures update live as the market moves.
Swaps on a market-cap-weighted healthcare index, rebalanced daily. The index is concentrated in the largest pharmaceutical and managed-care names, so CURE reflects the fortunes of a handful of very large companies rather than the sector's breadth.
The distinction is worth being clear about. CURE holds the big, cash-generative healthcare businesses; LABU holds an equal-weighted basket dominated by small biotech. Healthcare is traditionally defensive — demand for medicine does not fall in a recession — while biotech behaves like a high-beta growth sector. Tripling a defensive sector produces a very different risk profile from tripling a speculative one.
Drug pricing policy and Medicare reimbursement decisions, which can reprice the whole sector on a single headline. Also managed-care earnings, where medical cost ratios drive large moves, and any rotation into defensives during a risk-off period.